Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Published byMarina de Groot Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble."— Presentation transcript:

1 Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial (CHEST)-2 study. Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial (CHEST)-2 study. At 1 year, the estimated rate of clinical worsening-free survival was 88% and the estimated rate of survival was 97%. Reproduced from [44] with permission from the publisher. Marius M. Hoeper Eur Respir Rev 2015;24: ©2015 by European Respiratory Society

Download ppt "Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble."

Similar presentations

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.
Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.

Schematic representation of the potential clinical courses of idiopathic pulmonary fibrosis. Schematic representation of the potential clinical courses.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Timeline of approval of therapies for pulmonary arterial hypertension.

Timeline of approval of therapies for pulmonary arterial hypertension.
Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.
Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.
The distribution of the extent of change in inspiratory capacity (IC) during exercise is shown in moderate-to-severe chronic obstructive pulmonary disease.

The distribution of the extent of change in inspiratory capacity (IC) during exercise is shown in moderate-to-severe chronic obstructive pulmonary disease.
Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.
Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.
Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)
Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;
Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.
3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).
Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.

Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.
Profile of Pseudomonas aeruginosa resistance by country and antibiotic

Profile of Pseudomonas aeruginosa resistance by country and antibiotic
Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.
The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Similar presentations

Ads by Google